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Gamma delta T cells (gdT) are potent mediators of antitumor cytotoxicity and have shown promising efﬁcacy in early
phase clinical trials. Most is known about the tumoricidal properties of cells bearing the Vd2 T cell receptor chain, but
recent studies have demonstrated that cells with the Vd1 chain and those with neither Vd1 nor Vd2 chains have
properties which may make them more attractive anticancer effectors in adoptive immunotherapy.
For a cell type to be useful in cancer
adoptive immunotherapy it must be ame-
nable to ex vivo expansion of potent effec-
tors in a manner that avoids generation of
regulatory or suppressive counterparts.
With this in mind, numerous cell popula-
tions have been evaluated over the past
20 y, including dendritic cells, lympho-
kine activated killer (LAK) cells, tumor
infiltrating lymphocytes, and positively
selected natural killer (NK) cells. How-
ever, each method has limitations that
have precluded widespread clinical adop-
tion. For example, the difficulty in obtain-
ing sufficient numbers of tumor
infiltrating lymphocytes for most cancer
types, and the expansion of regulatory
T-cells in response to IL-2.
gdT lymphocytes have also been evalu-
ated for ex vivo expansion for adoptive
immunotherapy and equally confounding
hurdles to overcome have been revealed.
While gdT cell adoptive immunotherapy
using existing technologies demonstrates
modest but promising clinical effect,1 new
approaches are required for effective utili-
zation of this unique population of cells.
There are a number of key differences
between peripherally circulating gdT cells
and the more abundant alpha beta T
(abT) lymphocytes. Most notably, gdT
cells recognize targets in an MHC
independent manner, have innate killing
activity against pathogens, and appear to
respond to self-molecules that signal
potential danger or cellular stress. Further-
more, they can differentiate into profes-
sional antigen presenting cells (pAPCs),
expressing co-stimulatory molecules and
presenting antigenic fragments for the pri-
mary stimulation of CD4C and CD8C
ab T-cell responses.2,3
In the peripheral blood of individuals
living outside areas of endemic parasitae-
mia, gdT cells expressing the Vg9Vd2
TCR are the commonest subset. In parts of
Africa, however, the Vd1C subset predomi-
nates,4 and there is evidence of extra-thy-
mic changes in gdT cell repertoire in
response to environmental pathogen expo-
sure. Until recently, almost all human gdT
cell research focused on the Vg9Vd2 sub-
set, due to its relative abundance in West-
ern populations and ease of expanding
large numbers of cells for study or adoptive
transfer using phosphoantigen ligands of
the Vg9Vd2 TCR. Deniger and colleag-
ues 5,6 demonstrated that polyclonal gdT
cell expansion was possible using an engi-
neered K562 cell line expressing CD86,
CD64, 41BBL, and membrane bound IL-
15. Using the same artificial antigen pre-
senting cells (aAPC) coated in an anti-
gdTCR antibody (Biolegend clone B1) we
have shown that it is possible to generate
>1,000 fold expansion of gdT cells from
the blood of neuroblastoma patients within
1 mo, preserving the relative distributions
of Vd1C, Vd2C and Vd1neg/Vd2neg gdT
subtypes7 (Fig. 1).
Vd1C and Vd1neg/Vd2neg gdT cells
expanded using aAPCCB1 demonstrate
many characteristics that recommend
them for cellular immunotherapy over
Vg9Vd2C cells. Following adoptive trans-
fer, less differentiated cells persist for lon-
ger in the recipient. Vd1C and Vd1neg/
Vd2neg gdT cells show a less differentiated
pattern of CD27, CD45RA, and CD62L
expression both before and after expansion
with aAPCCB1 compared to Vd2C gdT
cells. PD-1 is a marker associated with T-
cell exhaustion, and has been a key target
in therapies aimed at overcoming immune
checkpoints.8 Vd1C and Vd1neg/Vd2neg
gdT cells have lower expression of PD-1
compared to both Vd2C and abT cells
after 2 weeks of expansion, which is suffi-
cient to generate around 50-fold expan-
sion in gdT cell numbers. Perhaps most
significantly however is the striking level
of innate cytotoxicity demonstrated by
Vd1C gdT cells against solid tumor cell
lines. It has been known for some time
that phosphoantigen expanded Vd2C
gdT cells will kill cell lines from certain
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solid and hematological malignancies, but
with only a few exceptions this killing is
significantly antibody dependent.1
We showed that Vd1C cytotoxicity
against the same targets was independent
of antibody and not attributable to allor-
eactivity, with killing efficiency equivalent
or greater than the ability of Vd2C gdT
cells to kill opsonized target cells; Vd2C
cytotoxicity in the absence of opsonizing
antibody was minimal. Based on these
data, it is perhaps unsurprising that the
published clinical trials of gdT cell immu-
notherapy, all of which used Vd2C cell
expansions and none of which combined
the therapy with an antitumor antibody,
showed only modest efficacy.1,9 Compari-
son of our recent studies with the work of
Deniger et al. highlights differences in the
innate cytolytic potential of Vd2C gdT
cells following expansion under differing
conditions. These differences could be
explained by different starting populations
(umbilical cord blood vs. PBMC), differ-
ent cytokines during expansion or differ-
ent engagement of the gdTCR in the
models used.
To be useful in cancer immunotherapy,
an expanded effector population must pos-
sess certain characteristics. They require
tumor tropism to infiltrate the tumor in
sufficient numbers. Their memory pheno-
types must be sufficiently na€ıve to allow
survival in the host following adoptive
transfer, and their cytolytic activity must
be specific for tumor cells. Non-Vd2C gdT
cells, and especially Vd1C
cells fulfil this wide spectrum
of requirements, encouraging
the therapeutic exploitation
of these subsets. Moreover,
their innate cytotoxic mecha-
nisms will result in the release
of antigen for uptake. The
exposure to tumor antigen
will thus activate their expan-
sion and simultaneously acti-




The propensity of Vd2C
gdT cells to activation
induced death ,10 combined
with their higher levels of
differentiation and expres-
sion of exhaustion markers 7
suggest that they may not be
the best choice of effector,
despite the ease in expanding
large numbers. Deniger
et al.’s use of umbilical cord blood as a
more na€ıve source of cells may go some
way to overcoming this limitation and is
of particular interest.
Therefore, despite the moderate clini-
cal success of Vd2C gdT cell based immu-
notherapy, there is an opportunity to
explore the utility of non-Vd2C gdT cells
as adoptive transfer agents. These could be
delivered either as selected populations or
as polyclonal gdT cell preparations, which
harness the different antigenic affinities,
cytolytic and antigen presentation profiles
of each subset.
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